Drugs / GLA-SE
GLA-SE
also known as
Glucopyranosyl Lipid A - Stable Emulsion · Glucopyranosyl Lipid A- Stable oil-in-water emulsion · AP 10-201 · glucopyranosil lipid adjuvant stable emulsion · Glucopyranosyl lipid A · Glucopyranosyl Lipid A in Stable Emulsion · Glucopyranosyl Lipid Adjuvant-Stable Emulsion · Glucopyranosyl-lipid adjuvant in squalene emulsion · +1 more
Other / unclassified targets TLR4 via activation
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02320305 | Jan → Dec 2015 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT06714513 | May 2025 → Dec 2026 expected | pulmonary tuberculosis | Quratis Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06627257 | Jan 2025 → Mar 2026 overdue | leprosy | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05292391 | May 2022 → Mar 2024 | schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04607408 | Nov 2020 → Jul 2024 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT03982121 | Jun 2019 → Feb 2020 | colorectal cancer | Gustave Roussy, Cancer Campus, Grand Paris | Withdrawn | No outcome recorded |
| Phase 1 | NCT03806699 | Apr 2019 → Sep 2020 | tuberculosis | Quratis Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02658253 | Jan 2016 → Sep 2018 | malaria | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT02508376 | Oct 2015 → Aug 2017 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02180698 | Nov 2014 → Oct 2016 | soft tissue sarcoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02071758 | Apr 2014 → Dec 2015 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01949909 | Mar 2014 → Jul 2015 | malaria | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT02014727 | Jan 2014 → Mar 2015 | Plasmodium falciparum malaria | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT02035657 | Jan 2014 → Mar 2018 | cutaneous neuroendocrine carcinoma | Immune Design | Completed | No outcome recorded |
| Phase 1 | NCT01927159 | Sep 2013 → Jul 2015 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01751048 | Mar 2013 → Jan 2015 | leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01599897 | Aug 2012 → May 2014 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01540474 | Feb → Oct 2012 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT01484548 | Jan → Aug 2012 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT05999825 | Sep 2024 → Apr 2025 | Schistosoma mansoni infectious disease | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03806686 | May 2018 → Mar 2020 | tuberculosis | Quratis Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03041766 | Dec 2016 → Apr 2017 | schistosomiasis | Oswaldo Cruz Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02465216 | Jun 2015 → Jan 2017 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | Met primary |
| Phase 2 | NCT01991561 | Jun 2013 → Jul 2014 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT05762393 Background | Nov 2023 → May 2025 | schistosomiasis | International Vaccine Institute | Completed | No outcome recorded |
| Phase 1 | NCT05182125 Background | Nov 2021 → Aug 2023 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT03722472 Background | Oct 2018 → Jun 2020 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT03302897 Background | Oct 2017 → Mar 2019 | leprosy | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT02647489 Background | May 2016 → Nov 2017 | malaria | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1 | NCT02015416 Background | Nov 2013 → Dec 2016 | breast cancer, melanoma, non-small cell lung carcinoma, ovarian cancer +1 | Immune Design | Completed | No outcome recorded |
| Phase 1/2 | NCT03947437 Background | Feb → Mar 2024 | leprosy | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
| Phase 2 | NCT05658614 Background | Jul 2022 → Sep 2023 | Schistosoma mansoni infectious disease | Oswaldo Cruz Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT03799510 Background | Dec 2018 → Jul 2019 | schistosomiasis | Oswaldo Cruz Foundation | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | Quratis Inc. | 우스터 HIV 백신사와 GLA-SE 어주번트 임상시험 공급계약 체결 quratis.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLA-SE | “intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)” NCT01949909 ↗33“2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.” NCT06627257 ↗ “The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.” NCT06714513 ↗ “NY-ESO-1 recombinant protein together with GLA-SE” NCT02015416 ↗ “GLA-SE” NCT02320305 ↗ |
| Known as | AP 10-201 | “GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])” NCT05182125 ↗ |
| Known as | glucopyranosil lipid adjuvant stable emulsion | “P27A antigen (10 or 50 μg), adjuvanted with Alhydrogel or glucopyranosil lipid adjuvant stable emulsion (GLA-SE; 2.5 or 5 μg), or control rabies vaccine (Verorab) were...” PMID 29945169 ↗ Jan 2019 |
| Known as | Glucopyranosyl lipid A | “GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection” NCT05658614 ↗ |
| Known as | Glucopyranosyl Lipid A - Stable Emulsion | “The vaccine consists of the recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (Glucopyranosyl Lipid A - Stable...” NCT03302897 ↗1“Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant” NCT01540474 ↗ |
| Known as | Glucopyranosyl Lipid A in Stable Emulsion | “Glucopyranosyl Lipid A in Stable Emulsion” NCT03041766 ↗ |
| Known as | Glucopyranosyl Lipid A- Stable oil-in-water emulsion | “Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE.” NCT01751048 ↗1“Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57” NCT02508376 ↗ |
| Known as | Glucopyranosyl Lipid Adjuvant-Stable Emulsion | “Glucopyranosyl Lipid Adjuvant-Stable Emulsion” NCT03041766 ↗ |
| Known as | Glucopyranosyl-lipid adjuvant in squalene emulsion | “Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE)” NCT01991561 ↗ |
| Known as | Toll-like Receptor 4 Agonist GLA-SE | “Toll-like Receptor 4 Agonist GLA-SE” NCT03041766 ↗ |
| Action | Activate | “The TLR-4 agonist adjuvant, GLA-SE” PMID 30210819 ↗ Sep 2018 |
| Modality | Other / unclassified | “a proprietary adjuvant” NCT01540474 ↗ |
| Route | Intramuscular | “Administered Intramuscularly” NCT01540474 ↗ |
| Target | TLR4 | “a Toll-like Receptor-4 Agonist” NCT02035657 ↗ |